Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,646 SEK | +0.11% | -1.94% | +21.68% |
05-16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
05-16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.68% | 239B | - | ||
+32.06% | 694B | C+ | ||
+29.38% | 593B | B | ||
-1.62% | 371B | C+ | ||
+19.80% | 331B | B- | ||
+6.70% | 290B | C+ | ||
-2.99% | 209B | A+ | ||
+10.05% | 209B | B- | ||
+8.07% | 169B | C+ | ||
-0.52% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- AZN Stock
- Ratings AstraZeneca PLC